Recent Finacing
Recent Raise
Amygdala Neurosciences develops selective, orally bioavailable ALDH2 inhibitors and small-molecule pharmacotherapies for alcohol, opioid, nicotine, and binge-eating disorders, advancing programs from IND-enabling preclinical to Phase 2.
